June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Safety and Efficacy of Anti-VEGF Therapy for Choroidal Neovascularization Overlying Choroidal Osteoma
Author Affiliations & Notes
  • Mohammed Khan
    Ophthalmology, Wills Eye Institute, Philadelphia, PA
  • Francis DeCroos
    Retina Service, Wills Eye Institute, Philadelphia, PA
  • Philip Storey
    Retina Service, Wills Eye Institute, Philadelphia, PA
  • Jerry Shields
    Oncology Service, Wills Eye Institute, Philadelphia, PA
  • Sunir Garg
    Retina Service, Wills Eye Institute, Philadelphia, PA
  • Carol Shields
    Oncology Service, Wills Eye Institute, Philadelphia, PA
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 5885. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Mohammed Khan, Francis DeCroos, Philip Storey, Jerry Shields, Sunir Garg, Carol Shields; Safety and Efficacy of Anti-VEGF Therapy for Choroidal Neovascularization Overlying Choroidal Osteoma. Invest. Ophthalmol. Vis. Sci. 2013;54(15):5885.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To investigate the safety and efficacy of intravitreal bevacizumab or ranibizumab therapy for treatment of choroidal neovascularization (CNV) associated with choroidal osteoma.

Methods: Retrospective, observational, consecutive case series of patients diagnosed with choroidal osteoma and CNV who were treated with intravitreal bevacizumab and/or ranibizumab, on the Retina or Oncology Services of the Wills Eye Hospital, Philadelphia, PA.

Results: Six tumors in six eyes were treated with intravitreal anti-VEGF therapy. Mean tumor basal diameter was 8.9 mm (range 4.5 - 14 mm), with mean tumor thickness 1.2 mm (range 1.0 - 1.6 mm). A mean of 10 intravitreal injections were completed (median 9, range 3 - 19 injections), with regression of CNV and resolution of fluid on optical coherence tomography achieved in 5 of 6 (83%) cases. Two tumors required 1 session of photodynamic therapy (PDT) for control in addition to anti-VEGF therapy. Improvement or stability of visual acuity was observed in 5 of 6 eyes (83%, range 0 to 6 Snellen line improvement). Patients were followed over a mean period of 21 months (median 18, range 5 to 56 months), with one complication (traumatic cataract) observed.

Conclusions: Therapy with intravitreal bevacizumab and/or ranibizumab can be effective for CNV secondary to choroidal osteoma, with resolution of CNV and preservation of visual acuity.

Keywords: 744 tumors • 453 choroid: neovascularization  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×